Amgen to trim workforce by up to 14%

Share this article:

Amgen announced yesterday that it would reduce company staff by up to 14% due to lower Aranesp sales.

Sales of Amgen's kidney disease-related and chemotherapy-induced anemia Aranesp fell 19% to $578 million in the second quarter from $713 million a year earlier.

"It's the first time in our 27-year history we've had to restructure," Kevin Sharer, Amgen's CEO told The Wall Street Journal. "…Virtually any company with any scale has gone through this kind of event. It's our turn," he said.

Amgen employees were expected to receive a video on their desktops today detailing the restructuring plan.

Sharer has publically rejected analysts' calls for a sales force consolidation, stating the force was already lean enough and was warranted due to its specialization in nephrology and oncology.

Amgen did not immediately return MM&M's call seeking more information on the areas of the company affected by the announced cuts.

Share this article:

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...